Halozyme appoints new president, CEO

The company has promoted Michael Shepard as the chief scientific officer after having joined the company as vice president of discovery research.

Halozyme president and CEO Gregory Frost said that he is passionate about Halozyme’s future, their technology platform, and have confidence in the team to achieve the goals.

"With the promotion of Mike Shepard to chief scientific officer, our scientific leadership has been placed in the capable hands of a proven biotechnology product innovator," Frost said.

Halozyme Therapeutics is a biopharmaceutical company developing and commercialising products targeting the extracellular matrix for the drug delivery, endocrinology, oncology and dermatology markets.